Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 14Thoracic 2Myeloid 1Head & Neck 1Gynecologic 1Genitourinary 1Endocrine 1Dermatologic 1CNS 1

Conditions

Thyroid Neoplasms 1Lung Neoplasms 1Histiocytosis 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1

Interventions

Cisplatin 85pembrolizumab 76Magnetic Resonance Spectroscopy 46Radiotherapy, Intensity-Modulated 41Specimen Handling 36Cetuximab 36Carboplatin 35Radiotherapy 34Nivolumab 28Paclitaxel 24Radiation 22Platinum 22Docetaxel 20Biopsy 201,2-diaminocyclohexaneplatinum II citrate 20Gemcitabine 19Surveys and Questionnaires 15Fluorouracil 14toripalimab 13Standard of Care 12Taxes 11cemiplimab 9atezolizumab 9Ipilimumab 9Drug Therapy 9Cyclophosphamide 9X-Rays 8Surgical Procedures, Operative 8Radiosurgery 7Immunoglobulin G 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
IFL protocol × Head & Neck × 90 days × Clear all
NCT05786924 2026-04-21

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Servier

Phase 1/2 Recruiting
554 enrolled
CNSGastrointestinalHead & NeckMyeloidThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Histiocytosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡